Skip to main content
NCBI home page
Mediators of Inflammation logoLink to Mediators of Inflammation
. 1993;2(7):S21–S23. doi: 10.1155/S0962935193000705

Vulnerability of vascular endothelium in lipopolysaccharide toxicity: effect of (acyl) carnitine on endothelial stability

W C Hülsmann 1,✉
PMCID: PMC2365446  PMID: 18475564

Abstract

The literature presented illustrates that lipopolysaccharide (LPS), from bacterial cell walls, induces tumour necrosis factor (TNF) synthesis in macrophages. TNF affects a number of cell types, amongst which are endothelial cells, within a few hours. Its injection has been shown to produce all symptoms of the toxic syndrome. In the present communication the vulnerability of endothelial cells will be stressed. These cells require carnitine not only for fatty acid oxidation but also for membrane protection and repair. As endothelial cells lose carnitine during hypoperfusion, it is speculated that the supply of carnitine during the early phase of LPS toxicity in rats might delay or avoid loss of endothelial functions. Earlier it was observed that hearts from rats, injected 3 h previously with LPS, showed strongly increased interstitial fluid production compared to hearts from control rats, even when TNF was present during a 3 h in vitro perfusion. It showed that LPS in vivo generates factors other than TNF, such as platelet activating factor (PAF), that are responsible for the increased capillary permeability.

Full Text

The Full Text of this article is available as a PDF (296.3 KB).

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Anggård E. E. The endothelium--the body's largest endocrine gland? J Endocrinol. 1990 Dec;127(3):371–375. doi: 10.1677/joe.0.1270371. [DOI] [PubMed] [Google Scholar]
  2. Beutler B., Cerami A. Cachectin and tumour necrosis factor as two sides of the same biological coin. Nature. 1986 Apr 17;320(6063):584–588. doi: 10.1038/320584a0. [DOI] [PubMed] [Google Scholar]
  3. Beutler B., Greenwald D., Hulmes J. D., Chang M., Pan Y. C., Mathison J., Ulevitch R., Cerami A. Identity of tumour necrosis factor and the macrophage-secreted factor cachectin. Nature. 1985 Aug 8;316(6028):552–554. doi: 10.1038/316552a0. [DOI] [PubMed] [Google Scholar]
  4. Beutler B., Mahoney J., Le Trang N., Pekala P., Cerami A. Purification of cachectin, a lipoprotein lipase-suppressing hormone secreted by endotoxin-induced RAW 264.7 cells. J Exp Med. 1985 May 1;161(5):984–995. doi: 10.1084/jem.161.5.984. [DOI] [PMC free article] [PubMed] [Google Scholar]
  5. Bevilacqua M. P., Pober J. S., Majeau G. R., Fiers W., Cotran R. S., Gimbrone M. A., Jr Recombinant tumor necrosis factor induces procoagulant activity in cultured human vascular endothelium: characterization and comparison with the actions of interleukin 1. Proc Natl Acad Sci U S A. 1986 Jun;83(12):4533–4537. doi: 10.1073/pnas.83.12.4533. [DOI] [PMC free article] [PubMed] [Google Scholar]
  6. Breviario F., Proserpio P., Bertocchi F., Lampugnani M. G., Mantovani A., Dejana E. Interleukin-1 stimulates prostacyclin production by cultured human endothelial cells by increasing arachidonic acid mobilization and conversion. Arteriosclerosis. 1990 Jan-Feb;10(1):129–134. doi: 10.1161/01.atv.10.1.129. [DOI] [PubMed] [Google Scholar]
  7. Clark M. A., Chen M. J., Crooke S. T., Bomalaski J. S. Tumour necrosis factor (cachectin) induces phospholipase A2 activity and synthesis of a phospholipase A2-activating protein in endothelial cells. Biochem J. 1988 Feb 15;250(1):125–132. doi: 10.1042/bj2500125. [DOI] [PMC free article] [PubMed] [Google Scholar]
  8. Exley A. R., Cohen J., Buurman W., Owen R., Hanson G., Lumley J., Aulakh J. M., Bodmer M., Riddell A., Stephens S. Monoclonal antibody to TNF in severe septic shock. Lancet. 1990 May 26;335(8700):1275–1277. doi: 10.1016/0140-6736(90)91337-a. [DOI] [PubMed] [Google Scholar]
  9. Fràter-Schröder M., Risau W., Hallmann R., Gautschi P., Böhlen P. Tumor necrosis factor type alpha, a potent inhibitor of endothelial cell growth in vitro, is angiogenic in vivo. Proc Natl Acad Sci U S A. 1987 Aug;84(15):5277–5281. doi: 10.1073/pnas.84.15.5277. [DOI] [PMC free article] [PubMed] [Google Scholar]
  10. Geeraerts M. D., Ronveaux-Dupal M. F., Lemasters J. J., Herman B. Cytosolic free Ca2+ and proteolysis in lethal oxidative injury in endothelial cells. Am J Physiol. 1991 Nov;261(5 Pt 1):C889–C896. doi: 10.1152/ajpcell.1991.261.5.C889. [DOI] [PubMed] [Google Scholar]
  11. Glauser M. P., Zanetti G., Baumgartner J. D., Cohen J. Septic shock: pathogenesis. Lancet. 1991 Sep 21;338(8769):732–736. doi: 10.1016/0140-6736(91)91452-z. [DOI] [PubMed] [Google Scholar]
  12. Hülsmann W. C., Dubelaar M. L. Aspects of fatty acid metabolism in vascular endothelial cells. Biochimie. 1988 May;70(5):681–686. doi: 10.1016/0300-9084(88)90253-2. [DOI] [PubMed] [Google Scholar]
  13. Hülsmann W. C., Dubelaar M. L. Carnitine requirement of vascular endothelial and smooth muscle cells in imminent ischemia. Mol Cell Biochem. 1992 Oct 21;116(1-2):125–129. doi: 10.1007/BF01270579. [DOI] [PubMed] [Google Scholar]
  14. Hülsmann W. C., Dubelaar M. L., De Wit L. E., Persoon N. L. Cardiac lipoprotein lipase: effects of lipopolysaccharide and tumor necrosis factor. Mol Cell Biochem. 1988 Feb;79(2):137–145. doi: 10.1007/BF02424556. [DOI] [PubMed] [Google Scholar]
  15. Hülsmann W. C., Dubelaar M. L. Early damage of vascular endothelium during cardiac ischaemia. Cardiovasc Res. 1987 Sep;21(9):674–677. doi: 10.1093/cvr/21.9.674. [DOI] [PubMed] [Google Scholar]
  16. Hülsmann W. C., Dubelaar M. L. Effects of tumor necrosis factor (TNF) on lipolytic activities of rat heart. Mol Cell Biochem. 1988 Feb;79(2):147–151. doi: 10.1007/BF02424557. [DOI] [PubMed] [Google Scholar]
  17. Hülsmann W. C., Lamers J. M., Stam H., Breeman W. A. Calcium overload in endotoxemia. Life Sci. 1981 Sep 7;29(10):1009–1014. doi: 10.1016/0024-3205(81)90459-8. [DOI] [PubMed] [Google Scholar]
  18. Langeler E. G., Fiers W., van Hinsbergh V. W. Effects of tumor necrosis factor on prostacyclin production and the barrier function of human endothelial cell monolayers. Arterioscler Thromb. 1991 Jul-Aug;11(4):872–881. doi: 10.1161/01.atv.11.4.872. [DOI] [PubMed] [Google Scholar]
  19. Moncada S., Gryglewski R., Bunting S., Vane J. R. An enzyme isolated from arteries transforms prostaglandin endoperoxides to an unstable substance that inhibits platelet aggregation. Nature. 1976 Oct 21;263(5579):663–665. doi: 10.1038/263663a0. [DOI] [PubMed] [Google Scholar]
  20. Nawroth P. P., Stern D. M. Modulation of endothelial cell hemostatic properties by tumor necrosis factor. J Exp Med. 1986 Mar 1;163(3):740–745. doi: 10.1084/jem.163.3.740. [DOI] [PMC free article] [PubMed] [Google Scholar]
  21. Pennica D., Nedwin G. E., Hayflick J. S., Seeburg P. H., Derynck R., Palladino M. A., Kohr W. J., Aggarwal B. B., Goeddel D. V. Human tumour necrosis factor: precursor structure, expression and homology to lymphotoxin. Nature. 1984 Dec 20;312(5996):724–729. doi: 10.1038/312724a0. [DOI] [PubMed] [Google Scholar]
  22. Prescott S. M., Zimmerman G. A., McIntyre T. M. Human endothelial cells in culture produce platelet-activating factor (1-alkyl-2-acetyl-sn-glycero-3-phosphocholine) when stimulated with thrombin. Proc Natl Acad Sci U S A. 1984 Jun;81(11):3534–3538. doi: 10.1073/pnas.81.11.3534. [DOI] [PMC free article] [PubMed] [Google Scholar]
  23. Romano M., Molino M., Cerletti C. Endotoxic lipid A induces intracellular Ca2+ increase in human platelets. Biochem J. 1991 Aug 15;278(Pt 1):75–80. doi: 10.1042/bj2780075. [DOI] [PMC free article] [PubMed] [Google Scholar]
  24. Shukla S. D. Platelet-activating factor receptor and signal transduction mechanisms. FASEB J. 1992 Mar;6(6):2296–2301. doi: 10.1096/fasebj.6.6.1312046. [DOI] [PubMed] [Google Scholar]
  25. Waage A., Halstensen A., Espevik T. Association between tumour necrosis factor in serum and fatal outcome in patients with meningococcal disease. Lancet. 1987 Feb 14;1(8529):355–357. doi: 10.1016/s0140-6736(87)91728-4. [DOI] [PubMed] [Google Scholar]
  26. Ward P. A. Mechanisms of endothelial cell injury. J Lab Clin Med. 1991 Nov;118(5):421–426. [PubMed] [Google Scholar]
  27. van Hinsbergh V. W., Scheffer M. A. Effect of propionyl-L-carnitine on human endothelial cells. Cardiovasc Drugs Ther. 1991 Feb;5 (Suppl 1):97–105. doi: 10.1007/BF00128248. [DOI] [PubMed] [Google Scholar]

Articles from Mediators of Inflammation are provided here courtesy of Wiley

RESOURCES